Recombinant Human TGF-beta 2 Protein

Beta LifeScience SKU/CAT #: BL-1740NP
BL-1740NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1740NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human TGF-beta 2 Protein

Beta LifeScience SKU/CAT #: BL-1740NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Transforming Growth Factor Beta 2 is produced by our Mammalian expression system and the target gene encoding Ala303-Ser414 is expressed.
Accession P61812
Synonym Transforming growth factor beta-2; TGFB2; Polyergin; G-TSF; Glioblastoma-derived T-cell suppressor factor; Cetermin; BSC-1 cell growth inhibitor; TGF-beta-2
Gene Background Transforming growth factor beta-2 (TGF-β2) is a secreted protein which belongs to the TGF-beta family. It is known as a cytokine that performs many cellular functions and has a vital role during embryonic development. The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive. It is an extracellular glycosylated protein. It is known to suppress the effects of interleukin dependent T-cell tumors. Defects in TGFB2 may be a cause of non-syndromic aortic disease (NSAD).
Molecular Mass 12.7 KDa
Apmol Mass 12 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of 4mM HCl.
Endotoxin Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Biologically active. Please contact us to obtain bioactivity data.
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.; Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix. Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2.; Transforming growth factor beta-2: Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix. At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus. Once activated following release of LAP, TGF-beta-2 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.
Subcellular Location [Latency-associated peptide]: Secreted, extracellular space, extracellular matrix.; [Transforming growth factor beta-2]: Secreted.
Protein Families TGF-beta family
Database References

HGNC: 11768

OMIM: 190220

KEGG: hsa:7042

UniGene: Hs.133379

Associated Diseases Loeys-Dietz syndrome 4 (LDS4)

Gene Functions References

  1. Furthermore, upregulation of miR-328 could further repress the expression of TGF-beta2 and ECM proteins. In conclusion, this study demonstrated that miR-328 could prevent renal fibrogenesis by directly targeting TGF-beta2. Our findings suggested that elevated renal miR-328 levels might be a novel therapeutic strategy for treating renal fibrosis PMID: 30160133
  2. Importantly, high expression levels of HIF-1alpha/TGF-beta2/GLI2 correlated robustly with the patient relapse following chemotherapy, highlighting a potential biomarker and therapeutic target for chemoresistance in colorectal cancer. PMID: 29891662
  3. these data suggest that miR-592 may exert it suppressive role in breast cancer, at least in part, by targeting TGFbeta-2, and that miR-592 may be a novel target for breast cancer treatment PMID: 29039599
  4. MicroRNA-486-5p suppresses TGFB2-induced proliferation, invasion and epithelial-mesenchymal transition of lens epithelial cells by targeting Smad2. PMID: 29229876
  5. Results show that TGF-beta2 is highly expressed in glioma and correlated with poor prognosis in glioma patients. Further findings elucidate a potential mechanism of autophagy-associated glioma invasion that TGF-beta2 could initiate autophagy via Smad and non-Smad pathway to promote glioma cells' invasion. PMID: 29145888
  6. Up-regulation of TGF-beta2 showed a strong association with muscle invasion in bladder cancer. PMID: 28261684
  7. Report early adaptive drug-escape in EGFR-mutant lung tumor cells dependent on TGFbeta2-bioenergetics-mitochondrial priming. PMID: 27852038
  8. The expression of TGFB2 obtained by microarray analysis was consistent with that of RT-PCR. Ion transport could be affected promptly after ANP treatment, and subsequently, the cytolysis of vein endothelial cells may be promoted and endothelial permeability would be enhanced, followed by activated immune responses. PMID: 29279524
  9. 4.7 Mb deletion encompassing TGFB2 is associated with features of Loeys-Dietz syndrome and osteoporosis. PMID: 28544325
  10. results imply that the interaction of matrix AGEs with RAGE plays a role in the TGFbeta2-mediated EMT of lens epithelial cells and suggest that the blockade of RAGE could be a strategy to prevent PCO and other age-associated fibrosis. PMID: 27263094
  11. results support that the regulation of miR-30b by VEGF in HUVEC is important for capillary morphogenesis, as increased miR-30b expression inhibits capillary morphogenesis through enhanced expression of TGFbeta2 PMID: 28977001
  12. Data suggest that TGFB2 (the most abundant growth factor in human milk) binding to Tgfb2r elicits robust/rapid response in small intestinal mucosal cells leading to stimulation of Egr1 transport to nucleus and cell differentiation; more than 15 Wnt signaling pathway genes have Egr1 binding sites/response elements; Egr1 binds to Axin1 promoter and functionally activates gene expression. (Axin1 = axis inhibition protein 1) PMID: 27697743
  13. RUNX1T1 serves as a common angiogenic driver for vaculogenesis and functionality of endothelial lineage cells PMID: 28640846
  14. High TGFbeta2 expression is associated with oral cancer. PMID: 27803052
  15. TGF-beta2 is a new regulatory factor for KCC2 functional activation and membrane trafficking. PMID: 27505893
  16. Our data expand the phenotype of Loeys-Dietz syndrome type 4 : we confirm that TGFb2 mutations are responsible for true Loeys-Dietz (LDS) syndrome with non-specific features of connective tissue disorders and diffuse vascular lesions PMID: 27440102
  17. TGF-beta signaling regulated cell growth of cancer associated fibroblasts. PMID: 27880067
  18. Localized constitutive expression and release of TGF-beta2 by TM cells may promote or exacerbate elevation of IOP in POAG. PMID: 26743044
  19. Advanced glycation endproduct in the lens capsule promote the TGFbeta2-mediated fibrosis of lens epithelial cells. PMID: 26853893
  20. Our study suggests that lnc-ATB promotes tumor progression by interacting with miR-141-3p and that Lnc-ATB may be a valuable prognostic predictor for GC. In conclusion, the positive feedback loop of lnc-ATB/miR-141-3p/TGF-beta2 may be a potential therapeutic target for the treatment of GC. PMID: 28115163
  21. decorin can alter the bioactivity of TGF-beta2 on human myoblast migration PMID: 27644884
  22. findings indicate that lncRNA-ATB governs the autocrine secretion of TGF-beta2 in KFs, at least in part, by downregulating the expression level of ZNF217 via miR-200c, suggesting a signaling axis consisting of lncRNA-ATB/miR-200c/ZNF217/TGF-beta2 PMID: 27090737
  23. association between SNP rs6658835 in TGF-beta2 and conotruncal heart defects PMID: 27564654
  24. miR-422a directly targeted TGFbeta2 and regulated its expression and the activation of downstream molecules, smad2 and smad3 in osteosarcoma cells. PMID: 27779704
  25. miR-378a expression is associated with its methylation status in TGF-beta1-treated cells, and epigenetically-regulated miR-378a inhibits TGF-beta1-induced hepatic stellate cells activation, at least in part, via TGF-beta2. PMID: 27855367
  26. we detected and verified a list of differentially expressed microRNAs in PE placentas by HTS and qRT-PCR, and provided preliminary evidence for the role of miR-193b-3p in the pathogenesis of preeclampsia by targeting TGF-beta2. PMID: 26822621
  27. Likely pathogenic variants included a TGFB2 variant in one patient and a SMAD3 variant in another. These variants have been reported previously in individuals with similar phenotypes. Variants of uncertain significance of particular interest included novel variants in MYLK and MFAP5, which were identified in a third patient PMID: 26854089
  28. Results provide evidence that miR-148a decreases the expression of TGFbeta2 and SMAD2 in gastric cancer cells through binding to their 3'UTRs. PMID: 26983401
  29. TGF-beta2 induces epithelial-mesenchymal transition by activating the PI3K/Akt/mTOR signaling pathway in cultured human lens epithelial cells. PMID: 26647778
  30. Human retinal pigment epithelial cells were cultured in the presence or absence of TGF-beta2, and reverse-transcription quantitative PCR was performed to determine the mRNA expression of IDO and Nrf2. PMID: 26676103
  31. TGF-beta2 induces Grb2 to recruit PI3-K to TGF-RII that activates JNK/AP-1-signaling and augments invasiveness of Theileria-transformed macrophages. PMID: 26511382
  32. In conclusion, each of the DPP-4 inhibitors may have unique drug-specific effects. PMID: 26826382
  33. Active CREB1 promotes a malignant TGFbeta2 autocrine loop in glioblastoma. PMID: 25084773
  34. Comparison of the aqueous humor TGF-beta2 level between patients with open-angle glaucoma (OAG) and controls provides direct evidence for the role of TGF-beta2 in the etiology of OAG. (meta-analysis) PMID: 26019480
  35. there is a borderline significant association between higher mean TGF-beta2 levels in breast milk and more severe pathologic diagnoses PMID: 25604865
  36. These results suggest that miR-200a suppresses RCC development via directly targeting TGFB2, indicating that miR-200a may present a novel target for diagnostic and therapeutic strategies in renal cell carcinoma PMID: 25813153
  37. TGFbeta2 is a key growth promoter of CD44(hi) cells that survived chemotherapy and also is a growth inhibitor of cells that survived hypoxia. PMID: 26340918
  38. MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-beta2 PMID: 25793604
  39. High expression of TGFB2 is associated with melanoma. PMID: 25743834
  40. Data suggest that the intrinsic transforming growth factor beta 2-triggered stromal cell-derived factor-1-C-X-C chemokine receptor-4 signaling is crucial for drug resistance in bone marrow (BM)-slow-cycling disseminated tumor cells (DTCs). PMID: 25504440
  41. Here, we show that increased TGF-beta2 signaling through ALK5 plays a role in hypoxia-induced redifferentiation of chondrocytes. PMID: 25621374
  42. TGF-beta2 secretion from retinal pigmented epithelium decreases with polarization and becomes apically oriented PMID: 25496702
  43. glycated collagen in the cardiac interstitium triggers an autocrine TGF-beta2 signaling pathway that stimulates alpha11 integrin expression through Smad2/3 binding elements in the alpha11 integrin promoter PMID: 24962729
  44. these results revealed no correlation between the normalized expression of TGF-beta2, TGF-betaRI, or TGF-betaRII and EDSS scores PMID: 26037400
  45. these data shed light on previously unrecognized roles of Mkx in tendinopathy, tenogenesis, and tendon repair as well as in regulating the TGFbeta pathway. PMID: 25332192
  46. High levels of furin, TNF-alpha and TGF-beta2 may be the reason of proceeding decidualization, placentation, and prevention from abortion, in spite of terminating the fetal life. PMID: 26065233
  47. TGF-beta2 therefore promotes the adhesion and invasiveness of virulent macrophages by modulating COX2, EP4, and PKIG transcription to initiate a prostaglandin E2 (PGE2)-driven autostimulatory loop that augments PKA and EPAC activities. PMID: 25690101
  48. TGF-beta2 induced MYOC expression and secretion in human primary cultured trabecular meshwork cells PMID: 25197353
  49. Data indicate that TGF-beta2 (TGFB2) and TGF beta type III receptor (TGFBR3) are target genes of miR-193b in chondrogenesis. PMID: 25728278
  50. ALDH1 and TGFbeta2 play important roles in the development of breast cancer. PMID: 25120797


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed